[ad_1] SAN FRANCISCO and SUZHOU, China, Dec. 4, 2025 /PRNewswire/ — Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and become effective following the satisfaction of all closing […]
Tag: Innovent Biologics
Innovent’s PECONDLE® (Picankibart Injection) Received NMPA Approval
[ad_1] PECONDLE® (picankibart injection) has received approval from China’s National Medical Products Administration (NMPA) for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systematic therapy. PECONDLE® is the world’s first […]
Innovent Biologics Enters Hang Seng Index and Two Other Major Indices; Global Capital Markets Recognize Leading Innovator’s Value
[ad_1] SAN FRANCISCO and SUZHOU, China, Nov. 23, 2025 /PRNewswire/ — Innovent Biologics (Stock Code: 01801.HK), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology […]
Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints
[ad_1] SAN FRANCISCO and SUZHOU, China, Nov. 19, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular […]
Multiple Research Results from Innovent’s General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting
[ad_1] SAN FRANCISCO and SUZHOU, China, Nov. 4, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular […]
